Emgality 300 mg: The only FDA-approved treatment and dose specifically for your patients with episodic cluster headache^1,2

Recommended dosing with no titration required^1a

300 mg administered as 3 consecutive subcutaneous (SC) injections of 100 mg each, at the onset of the cluster period, and then monthly until the end of the cluster period.

• 300 mg dose; this comes in 3 x 100 mg prefilled syringes
• These 3 syringes are administered subcutaneously, one after another
• Patients begin treatment at the onset of a cluster period
• Patients take this 300 mg dose every month until their cluster period ends

Please review full Instructions for Use with your patients.

^aThe Emgality prefilled syringe needle is 27 gauge x 1/2 inch.³

Hypothetical dosing example¹

A patient with cluster periods lasting 7 weeks

Advise patients to^1,4:

• Store product refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect it from light until use
• Check expiration date on product prior to use

SELECT IMPORTANT SAFETY INFORMATION
Contraindication
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

How to administer Emgality

Preparation⁴

• Inspect the prefilled syringe and the medicine. Do not use the prefilled syringe and dispose of it if: it looks damaged, the expiration date printed on the label has passed, or the medicine is cloudy, discolored, has small particles, or is frozen
• Choose an area for injection: abdomen or thigh if self-injecting, or buttocks or back of upper arm if another person is injecting. Be sure to choose a different site (even within an area) for each injection
• Clean the site with an alcohol wipe and let it dry before injecting

The 3 key administration steps⁷

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

SELECT IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Watch how to use the Emgality prefilled syringe

Prescribing Information

Patient Information

Instructions for Use–100 mg syringe for episodic cluster headache

If you or your patients have any questions about Emgality, click the “Contact Lilly” button at the top of your screen, or call 1-833-EMGALITY (1-833-364-2548), to talk to a healthcare provider.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

How to locate and prescribe Emgality using the Electronic Media Record (EMR) system

SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.